Muscarinic receptor drug trihexyphenidyl can alter growth of mesenchymal glioblastoma in vivo

• Main Authors: Renfei Du (Author), Ahmed Y. Sanin (Author), Wenjie Shi (Author), Bing Huang (Author), Ann-Christin Nickel (Author), Andres Vargas-Toscano (Author), Shuran Huo (Author), Thomas Nickl-Jockschat (Author), Claudia A. Dumitru (Author), Wei Hu (Author), Siyu Duan (Author), I. Erol Sandalcioglu (Author), Roland S. Croner (Author), Joshua Alcaniz (Author), Wolfgang Walther (Author), Carsten Berndt (Author), Ulf D. Kahlert (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Glioblastoma (GBM) is the most commonly occurring and most aggressive primary brain tumor. Transcriptomics-based tumor subtype classification has established the mesenchymal lineage of GBM (MES-GBM) as cancers with particular aggressive behavior and high levels of therapy resistance. Previously it w...